Home > Oncology > SABCS 2021 > Phase 1–3 Trials > Datopotamab deruxtecan shows promising anti-tumour activity

Datopotamab deruxtecan shows promising anti-tumour activity

Presented By
Dr Ian Krop, Dana-Farber Cancer Institute, MA, USA

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
SABCS 2021
Trial
Phase 1, TROPION-PanTumor01
Updated results from the phase 1 TROPION PanTumor01 study confirm promising anti-tumour activity and a manageable safety profile of the antibody-drug conjugate datopotamab deruxtecan in patients with previously treated advanced/metastatic triple-negative breast cancer (TNBC). Effective treatment options for patients with advanced or metastatic TNBC that have relapsed or are refractory to standard treatment are limited. Over-expression of TROP2 was reported to predict poor prognosis in various solid tumours, including breast cancers [1]. Datopotamab deruxtecan is an antibody-drug conjugate consisting of a humanised anti-TROP2 IgG1 monoclonal antibody conjugated to a potent topoisomerase I inhibitor payload. Preliminary results from the multi-centre, open-label, phase 1 TROPION-PanTumor01 study (NCT0340138...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on